Abstract:This study demonstrated that intramural delivery of advanced c-myc neutrally charged antisense morpholino compound completely inhibits c-myc expression and dramatically reduces neointimal formation in a dose dependent fashion in a porcine coronary stent restenosis model, while allowing for complete vascular healing.
“…By using a local delivery balloon catheter, the neointimal volume obstruction and the angiographic restenosis rate wre not reduced (Table 1) (185). The clinical application of antisense ODN technology remains limited by a relative lack of specificity, slow uptake across the cell membrane and fast intracellular destruction of the ODN (186). It may be necessary to target more than one gene.…”
Section: Gene Therapy Approachmentioning
confidence: 99%
“…An advanced six-ring morpholino backbone c-myc antisense (AVI-4126 [Resten NG], AVI BioPharma, USA) with increased specificity was shown to inhibit c-myc expression and intimal hyperplasia after local catheter delivery in a porcine stent restenosis model (186). This new molecular configuration increased intracellular uptake, resisted enzymatic degradation and enhanced specificity to its target mRNA (186).…”
Section: Gene Therapy Approachmentioning
confidence: 99%
“…This new molecular configuration increased intracellular uptake, resisted enzymatic degradation and enhanced specificity to its target mRNA (186). Recently, the results of the AVAIL study, a phase II clinical trial evaluating intramural delivery of AVI-4126 in patients with focal de novo stenosis or ISR, were presented (188).…”
“…By using a local delivery balloon catheter, the neointimal volume obstruction and the angiographic restenosis rate wre not reduced (Table 1) (185). The clinical application of antisense ODN technology remains limited by a relative lack of specificity, slow uptake across the cell membrane and fast intracellular destruction of the ODN (186). It may be necessary to target more than one gene.…”
Section: Gene Therapy Approachmentioning
confidence: 99%
“…An advanced six-ring morpholino backbone c-myc antisense (AVI-4126 [Resten NG], AVI BioPharma, USA) with increased specificity was shown to inhibit c-myc expression and intimal hyperplasia after local catheter delivery in a porcine stent restenosis model (186). This new molecular configuration increased intracellular uptake, resisted enzymatic degradation and enhanced specificity to its target mRNA (186).…”
Section: Gene Therapy Approachmentioning
confidence: 99%
“…This new molecular configuration increased intracellular uptake, resisted enzymatic degradation and enhanced specificity to its target mRNA (186). Recently, the results of the AVAIL study, a phase II clinical trial evaluating intramural delivery of AVI-4126 in patients with focal de novo stenosis or ISR, were presented (188).…”
“…C-myc antisense oligonucleotides have also been shown to inhibit inflammation and extracellular matrix production. 14 However, the first clinical experience using catheter-based local delivery of c-myc antisense oligonucleotides was disappointing. 15…”
“…Promising results have been obtained with antisense oligonucleotides against NF B, 24 E2F 25 and cmyc. 26 Also, adenoviral Gax (growth arrest homeobox) gene transfer has been shown to reduce neointimal hyperplasia in stented rabbit iliac arteries. 27 The plateletderived growth factor (PDGF) gene family is one of the most potent chemoattractants of vascular SMC.…”
Section: Identification Of New Treatment Genes Has Provided More Oppomentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.